Raymond James & Associates »

Xilio Therapeutics shares owned by Raymond James & Associates

Quarter-by-quarter ownership of Xilio Therapeutics (XLO) shares owned by Raymond James & Associates from 13F filings

Historical chart of Raymond James & Associates investment in Xilio Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Xilio Therapeutics held by Raymond James & Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Xilio Therapeutics by Raymond James & Associates

Quarter filed Position value Share count Share price at filing
2024-09-30 $31k 39k 0.79
2024-06-30 $37k 39k 0.95

More positions owned by Raymond James & Associates

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Ishares Tr Core Msci Eafe (IEFA)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Ishares Tr Core S&p Mcp Etf (IJH)
Alphabet Cap Stk Cl A (GOOGL)
Meta Platforms Cl A (META)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Home Depot (HD)
UnitedHealth (UNH)

View all positions for Raymond James & Associates

Top funds holding Xilio Therapeutics

Bain Capital Life Sciences Investors
Rock Springs Capital Management
RiverVest Venture Management
Morgan Stanley
Vanguard Group
Renaissance Technologies
Balyasny Asset Management
Geode Capital Management
Bridgeway Capital Management
BlackRock
State Street Corporation
SevenBridge Financial
Raymond James & Associates
XTX Topco
Honkamp Krueger Financial Services

View all funds holding Xilio Therapeutics